// App-Quantinova.ai

BSH19‐PO‐065 : Successful treatment of chronic neutrophilic leukaemia and associated giant cell arteritis with the combination of ruxolitinib and azacytidine

Researchers

Presenter

  • N. Herlihy

Principal Investigators

  • N. Curto-Garcia

  • J. O'Sullivan

  • D. Radia

  • D. McLornan

  • S. Pye

  • R. Dillon

  • C. Harrison

Medical Centers

  • Guy’s and St. Thomas’ NHS Foundation Trust

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Autoimmune (AI)

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Giant cell arteritis

  • Rheumatoid arthritis

  • Thrombocytopenia

  • Inflammatory Arthritis

  • Aortic wall inflammation

  • Chronic myelomonocytic leukemia

Biomarkers

  • C reactive protein

  • Colony stimulating factor 3 receptor

  • Janus kinase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Methylprednisolone

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Hydroxycarbamide

  • Mycophenolic acid

  • Methotrexate

  • Vidaza

  • Ruxolitinib phosphate

  • Cytarabine liposomal

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved